BioVaxys Technology Corp.
BVAXF
$0.0389
$0.00010.26%
| 07/31/2024 | 04/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 63.49% | 40.84% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 63.49% | 40.84% | |||
| Operating Income | -63.49% | -40.84% | |||
| Income Before Tax | -116.79% | -204.17% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -116.79% | -204.17% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -116.79% | -204.17% | |||
| EBIT | -63.49% | -40.84% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -105.26% | -173.08% | |||
| Normalized Basic EPS | -58.33% | 0.00% | |||
| EPS Diluted | -105.26% | -173.08% | |||
| Normalized Diluted EPS | -58.33% | 0.00% | |||
| Average Basic Shares Outstanding | 5.68% | 43.35% | |||
| Average Diluted Shares Outstanding | 5.68% | 43.35% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
